Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
Dyne Therapeutics Analyst Ratings and Price Targets | NASDAQ:DYN | Benzinga
Dyne Therapeutics Inc has a consensus price target of $47.92 based on the ratings of 14 analysts. The high is $66 issued by Stifel on August 16, 2024. The low is $17 issued by JP Morgan on March 21, 2025. The 3 most-recent analyst ratings were released by JP Morgan, HC Wainwright & Co., and Chardan Capital on March 21, 2025, March 17, 2025, and March 17, 2025, respectively. With an average price target of $37.67 between JP Morgan, HC Wainwright & Co., and Chardan Capital, there's an implied 213.89% upside for Dyne Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
JP Morgan
HC Wainwright & Co.
Chardan Capital
BMO Capital
Scotiabank
1calculated from analyst ratings
Analyst Ratings for Dyne Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/21/2025 | Buy Now | 41.67% | JP Morgan | Tessa Romero62% | $18 → $17 | Maintains | Neutral | Get Alert |
| 03/17/2025 | Buy Now | 283.33% | HC Wainwright & Co. | Andrew Fein57% | $46 → $46 | Reiterates | Buy → Buy | Get Alert |
| 03/17/2025 | Buy Now | 316.67% | Chardan Capital | Keay Nakae58% | $50 → $50 | Maintains | Buy | Get Alert |
| 03/12/2025 | Buy Now | 316.67% | BMO Capital | Kostas Biliouris34% | → $50 | Initiates | → Outperform | Get Alert |
| 03/07/2025 | Buy Now | 316.67% | Scotiabank | Louise Chen59% | → $50 | Initiates | → Sector Outperform | Get Alert |
| 02/28/2025 | Buy Now | 316.67% | Chardan Capital | Keay Nakae58% | $50 → $50 | Maintains | Buy | Get Alert |
| 02/28/2025 | Buy Now | 300% | Piper Sandler | Edward Tenthoff52% | $53 → $48 | Maintains | Overweight | Get Alert |
| 02/28/2025 | Buy Now | 283.33% | HC Wainwright & Co. | Andrew Fein57% | $55 → $46 | Maintains | Buy | Get Alert |
| 01/24/2025 | Buy Now | — | Guggenheim | Debjit Chattopadhyay54% | — | Reiterates | Buy → Buy | Get Alert |
| 01/14/2025 | Buy Now | 275% | RBC Capital | Luca Issi40% | $45 → $45 | Reiterates | Outperform → Outperform | Get Alert |
| 01/13/2025 | Buy Now | 358.33% | HC Wainwright & Co. | Andrew Fein57% | $55 → $55 | Reiterates | Buy → Buy | Get Alert |
| 01/10/2025 | Buy Now | 316.67% | Chardan Capital | Keay Nakae58% | $50 → $50 | Maintains | Buy | Get Alert |
| 01/10/2025 | Buy Now | 358.33% | HC Wainwright & Co. | Andrew Fein57% | $55 → $55 | Reiterates | Buy → Buy | Get Alert |
| 12/13/2024 | Buy Now | 283.33% | Baird | Brian Skorney58% | → $46 | Initiates | → Outperform | Get Alert |
| 11/26/2024 | Buy Now | 275% | RBC Capital | Luca Issi40% | → $45 | Initiates | → Outperform | Get Alert |
| 11/13/2024 | Buy Now | 316.67% | Chardan Capital | Keay Nakae58% | $50 → $50 | Maintains | Buy | Get Alert |
| 11/13/2024 | Buy Now | 358.33% | HC Wainwright & Co. | Andrew Fein57% | $55 → $55 | Reiterates | Buy → Buy | Get Alert |
| 10/24/2024 | Buy Now | 191.67% | JP Morgan | Tessa Romero62% | $43 → $35 | Downgrade | Overweight → Neutral | Get Alert |
| 09/23/2024 | Buy Now | 341.67% | Piper Sandler | Edward Tenthoff52% | $53 → $53 | Reiterates | Overweight → Overweight | Get Alert |
| 09/04/2024 | Buy Now | 358.33% | HC Wainwright & Co. | Andrew Fein57% | $55 → $55 | Reiterates | Buy → Buy | Get Alert |
| 09/03/2024 | Buy Now | 358.33% | Oppenheimer | Francois Brisebois44% | $55 → $55 | Reiterates | Outperform → Outperform | Get Alert |
| 08/16/2024 | Buy Now | 450% | Stifel | Paul Matteis44% | $41 → $66 | Maintains | Buy | Get Alert |
| 08/15/2024 | Buy Now | 316.67% | Guggenheim | Debjit Chattopadhyay54% | $45 → $50 | Maintains | Buy | Get Alert |
| 08/14/2024 | Buy Now | 333.33% | Morgan Stanley | Michael Ulz57% | $48 → $52 | Maintains | Overweight | Get Alert |
| 08/13/2024 | Buy Now | 341.67% | Piper Sandler | Edward Tenthoff52% | $43 → $53 | Maintains | Overweight | Get Alert |
| 08/13/2024 | Buy Now | 358.33% | HC Wainwright & Co. | Andrew Fein57% | $48 → $55 | Maintains | Buy | Get Alert |
| 07/09/2024 | Buy Now | 258.33% | JP Morgan | Tessa Romero62% | $39 → $43 | Maintains | Overweight | Get Alert |
| 05/21/2024 | Buy Now | 250% | Chardan Capital | Keay Nakae58% | $31 → $42 | Maintains | Buy | Get Alert |
| 05/20/2024 | Buy Now | 250% | Jefferies | — | $36 → $42 | Maintains | Buy | Get Alert |
| 05/20/2024 | Buy Now | 300% | HC Wainwright & Co. | Andrew Fein57% | $46 → $48 | Maintains | Buy | Get Alert |
| 05/06/2024 | Buy Now | 158.33% | Chardan Capital | Keay Nakae58% | $31 → $31 | Maintains | Buy | Get Alert |
| 05/06/2024 | Buy Now | 291.67% | Oppenheimer | Francois Brisebois44% | $47 → $47 | Reiterates | Outperform → Outperform | Get Alert |
| 05/03/2024 | Buy Now | 200% | HC Wainwright & Co. | Andrew Fein57% | $36 → $36 | Reiterates | Buy → Buy | Get Alert |
| 04/30/2024 | Buy Now | 233.33% | Morgan Stanley | Michael Ulz57% | → $40 | Initiates | → Overweight | Get Alert |
| 03/26/2024 | Buy Now | 291.67% | Oppenheimer | Francois Brisebois44% | $47 → $47 | Reiterates | Outperform → Outperform | Get Alert |
| 03/08/2024 | Buy Now | 158.33% | Chardan Capital | Keay Nakae58% | $20 → $31 | Maintains | Buy | Get Alert |
| 03/07/2024 | Buy Now | 208.33% | Guggenheim | Debjit Chattopadhyay54% | $33 → $37 | Maintains | Buy | Get Alert |
| 03/06/2024 | Buy Now | 200% | HC Wainwright & Co. | Andrew Fein57% | $36 → $36 | Reiterates | Buy → Buy | Get Alert |
| 03/06/2024 | Buy Now | 241.67% | Stifel | Paul Matteis44% | $35 → $41 | Maintains | Buy | Get Alert |
| 03/06/2024 | Buy Now | 141.67% | Piper Sandler | Edward Tenthoff52% | $27 → $29 | Maintains | Overweight | Get Alert |
| 03/05/2024 | Buy Now | 291.67% | Oppenheimer | Francois Brisebois44% | $44 → $47 | Reiterates | Outperform → Outperform | Get Alert |
| 02/20/2024 | Buy Now | 200% | HC Wainwright & Co. | Andrew Fein57% | → $36 | Initiates | → Buy | Get Alert |
| 01/04/2024 | Buy Now | 366.67% | Raymond James | Steven Seedhouse58% | $27 → $56 | Maintains | Strong Buy | Get Alert |
| 08/09/2023 | Buy Now | 83.33% | JP Morgan | Tessa Romero62% | $20 → $22 | Maintains | Overweight | Get Alert |
| 08/04/2023 | Buy Now | 66.67% | Chardan Capital | Keay Nakae58% | → $20 | Reiterates | Buy → Buy | Get Alert |
| 03/03/2023 | Buy Now | 66.67% | Chardan Capital | Keay Nakae58% | $17 → $20 | Maintains | Buy | Get Alert |
| 02/27/2023 | Buy Now | 125% | Raymond James | Steven Seedhouse58% | $16 → $27 | Upgrade | Outperform → Strong Buy | Get Alert |
| 02/15/2023 | Buy Now | 183.33% | Oppenheimer | Francois Brisebois44% | → $34 | Initiates | → Outperform | Get Alert |
| 01/26/2023 | Buy Now | 175% | Guggenheim | Debjit Chattopadhyay54% | → $33 | Initiates | → Buy | Get Alert |
| 11/29/2022 | Buy Now | 50% | JP Morgan | Tessa Romero62% | $24 → $18 | Maintains | Overweight | Get Alert |
| 11/04/2022 | Buy Now | 33.33% | Raymond James | Steven Seedhouse58% | $15 → $16 | Maintains | Outperform | Get Alert |
| 07/20/2022 | Buy Now | 41.67% | Chardan Capital | Keay Nakae58% | → $17 | Initiates | → Buy | Get Alert |
| 07/12/2022 | Buy Now | 25% | Raymond James | Steven Seedhouse58% | → $15 | Initiates | → Outperform | Get Alert |
| 05/23/2022 | Buy Now | — | Piper Sandler | Edward Tenthoff52% | $16 → $12 | Maintains | Overweight | Get Alert |
FAQ
What is the target price for Dyne Therapeutics (DYN) stock?
The latest price target for Dyne Therapeutics (NASDAQ:DYN) was reported by JP Morgan on March 21, 2025. The analyst firm set a price target for $17.00 expecting DYN to rise to within 12 months (a possible 41.67% upside). 35 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Dyne Therapeutics (DYN)?
The latest analyst rating for Dyne Therapeutics (NASDAQ:DYN) was provided by JP Morgan, and Dyne Therapeutics maintained their neutral rating.
When was the last upgrade for Dyne Therapeutics (DYN)?
The last upgrade for Dyne Therapeutics Inc happened on February 27, 2023 when Raymond James raised their price target to $27. Raymond James previously had an outperform for Dyne Therapeutics Inc.
When was the last downgrade for Dyne Therapeutics (DYN)?
The last downgrade for Dyne Therapeutics Inc happened on October 24, 2024 when JP Morgan changed their price target from $43 to $35 for Dyne Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Dyne Therapeutics (DYN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Dyne Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Dyne Therapeutics was filed on March 21, 2025 so you should expect the next rating to be made available sometime around March 21, 2026.
Is the Analyst Rating Dyne Therapeutics (DYN) correct?
While ratings are subjective and will change, the latest Dyne Therapeutics (DYN) rating was a maintained with a price target of $18.00 to $17.00. The current price Dyne Therapeutics (DYN) is trading at is $12.00, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.